Female Infertility Market Size, Epidemiology, In-Market Drugs Sales, Pipeline Therapies, and Regional Outlook 2025-2035

Market Overview:

The female infertility market reached a value of USD 2.1 Billion across the top 7 markets (US, EU4, UK, and Japan) in 2024. Looking forward, IMARC Group expects the top 7 major markets to reach USD 2.8 Billion by 2035, exhibiting a growth rate (CAGR) of 2.87% during 2025-2035.

The female infertility market has been comprehensively analyzed in IMARC's new report titled "Female Infertility Market Size, Epidemiology, In-Market Drugs Sales, Pipeline Therapies, and Regional Outlook 2025-2035". Female infertility refers to a medical condition in which a woman is unable to conceive after a year of regular, unprotected intercourse or carry a pregnancy to term. The disorder often does not present itself with specific symptoms, and most women suffering from infertility do not experience any noticeable signs. However, some possible indications may include irregular or absent menstrual cycles, abnormal bleeding, pain or discomfort during intercourse, hormonal imbalances leading to acne or excessive hair growth, recurrent miscarriages, symptoms related to conditions like endometriosis or polycystic ovary syndrome (PCOS), etc. The diagnosis of female infertility involves a comprehensive evaluation performed by a fertility specialist or reproductive endocrinologist. The process typically begins with a thorough medical history review, such as discussions about menstrual cycles, previous pregnancies, any underlying health conditions, etc. Various diagnostic procedures may include blood tests to assess hormone levels and ovarian function, imaging studies like pelvic ultrasound to evaluate the reproductive organs, and other tests to examine ovulation and egg quality. In addition to this, numerous assessments, such as hysterosalpingography and laparoscopy, may be conducted to check the fallopian tubes.

The increasing cases of polycystic ovary syndrome (PCOS), hypothalamic dysfunction, premature ovarian insufficiency (POI), etc., that can disrupt normal ovulation are primarily driving the female infertility market. In addition to this, the rising incidence of several associated risk factors, including uterine abnormalities, pelvic adhesions, fallopian tube blockages, genetic disorders, etc., is also creating a positive outlook for the market. Moreover, the escalating utilization of hormone therapy to treat hormonal imbalances, as it aids in stimulating ovulation, enhancing follicle development, and supporting endometrial preparation for embryo implantation, is acting as another significant growth-inducing factor. Apart from this, the shifting preferences towards in-vitro maturation (IVM) over traditional in-vitro fertilization (IVF) since IVM eliminates the need for ovarian stimulation, thereby reducing the likelihood of ovarian hyperstimulation syndrome and offering a less invasive approach to fertility treatment, are further bolstering the market growth. Additionally, the ongoing advancements in preimplantation genetic testing (PGT), such as the introduction of PGT-A (aneuploidy screening), which helps in identifying embryos with chromosomal abnormalities, thus improving the chances of successful implantation and lowering the risk of miscarriage, are expected to drive the female infertility market during the forecast period.

IMARC Group's new report provides an exhaustive analysis of the female infertility market in the United States, EU4 (Germany, Spain, Italy, and France), the United Kingdom, and Japan. This includes treatment practices, in-market and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report, the United States has the largest patient pool for female infertility and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario, unmet medical needs, etc., have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the female infertility market in any manner.

Drugs:

Menopur injections are used to treat infertility in women. It promotes the regular development of an egg in a woman's ovary (female reproductive organ) and accelerates the release of a healthy, mature egg. This helps to cure infertility in women and raises the likelihood of a successful pregnancy. It is taken with an injection by a physician or nurse and should not be self-administered.

OVITRELLE/OVIDREL refers to the recombinant human chorionic gonadotropin (rhCG) in a pre-filled pen. It is recommended to treat women undergoing superovulation before assisted reproductive procedures, such as in vitro fertilization, to promote final follicular maturation and luteinization after stimulating follicular growth.

OXO‑001 by Oxolife is a first-in-class, non-hormonal oral small molecule (sodium tungstate) that acts directly on the endometrium, enhancing its receptivity to embryo implantation. In clinical studies, it promotes endometrial adhesion and invasion of the embryo by modulating key molecular pathways, thereby increasing implantation, ongoing pregnancy, and live birth rates in IVF/ICSI patients.

Time Period of the Study

• Base Year: 2024
• Historical Period: 2019-2024
• Market Forecast: 2025-2035

Countries Covered

• United States
• Germany
• France
• United Kingdom
• Italy
• Spain
• Japan

Analysis Covered Across Each Country

• Historical, current, and future epidemiology scenario
• Historical, current, and future performance of the female infertility market
• Historical, current, and future performance of various therapeutic categories in the market
• Sales of various drugs across the female infertility market
• Reimbursement scenario in the market
• In-market and pipeline drugs

Competitive Landscape:

This report also provides a detailed analysis of the current female infertility marketed drugs and late-stage pipeline drugs.

In-Market Drugs

• Drug Overview
• Mechanism of Action
• Regulatory Status
• Clinical Trial Results
• Drug Uptake and Market Performance

Late-Stage Pipeline Drugs

• Drug Overview
• Mechanism of Action
• Regulatory Status
• Clinical Trial Results
• Drug Uptake and Market Performance

*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.

Key Questions Answered in this Report:

Market Insights

• How has the female infertility market performed so far and how will it perform in the coming years?
• What are the markets shares of various therapeutic segments in 2024 and how are they expected to perform till 2035?
• What was the country-wise size of the female infertility across the seven major markets in 2024 and what will it look like in 2035?
• What is the growth rate of the female infertility across the seven major markets and what will be the expected growth over the next ten years?
• What are the key unmet needs in the market?

Epidemiology Insights

• What is the number of prevalent cases (2019-2035) of female infertility across the seven major markets?
• What is the number of prevalent cases (2019-2035) of female infertility by age across the seven major markets?
• What is the number of prevalent cases (2019-2035) of female infertility by gender across the seven major markets?
• What is the number of prevalent cases (2019-2035) of female infertility by type across the seven major markets?
• How many patients are diagnosed (2019-2035) with female infertility across the seven major markets?
• What is the size of the female infertility patient pool (2019-2024) across the seven major markets?
• What would be the forecasted patient pool (2025-2035) across the seven major markets?
• What are the key factors driving the epidemiological trend female infertility of?
• What will be the growth rate of patients across the seven major markets?

Female Infertility: Current Treatment Scenario, Marketed Drugs and Emerging Therapies

• What are the current marketed drugs and what are their market performance?
• What are the key pipeline drugs and how are they expected to perform in the coming years?
• How safe are the current marketed drugs and what are their efficacies?
• How safe are the late-stage pipeline drugs and what are their efficacies?
• What are the current treatment guidelines for female infertility drugs across the seven major markets?
• Who are the key companies in the market and what are their market shares?
• What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the female infertility market?
• What are the key regulatory events related to the female infertility market?
• What is the structure of clinical trial landscape by status related to the female infertility market?
• What is the structure of clinical trial landscape by phase related to the female infertility market?
• What is the structure of clinical trial landscape by route of administration related to the female infertility market?